Abl Bio Inc.

Uijung Jung

Yangsoon Lee

Eunyoung Park

Youngdon Pak

Hyejin Chung

Byungje Sung

Yeunju Kim

Lei Fang

Sang Hoon Lee

Eunsil Sung

Wenqing Jiang

Jinhyung Ahn

Kyeongsu Park

Kyungjin Park

Daehae Song

Yong-Gyu Son

Jaeho Jung

Seawon Ahn

YoungKwang Kim

Weon-Kyoo You

Yeun Ju Kim

Jun Hyun Jeong

Sang-Jun Ha

Myeong Joon Kim

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Anti-4-1BB antibody and use thereof

The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Growing community of inventors

Seongnam-Si, South Korea

Uijung Jung